Search the Newsreel

TSMC's Kumamoto Output Was Under 3%, But Tokyo Electron Kyushu's 91% Global Share Was the Supply Chain's True Weak Point

Rentokil Initial Number of Employees 2026 | Employee Count & Headcount Data

Rentokil Initial Plc had approximately 63,409 employees worldwide as of March 2026, marking a 1.7% decline since 2023. Despite this, the company is actively hiring, with 6,649 active job postings in 2026, an 18.3% increase from 2025. The workforce is primarily concentrated in the …

Rentokil Initial PLC (RTO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rentokil Initial PLC (RTO), covering its support, resistance, indicators, and moving averages. It compiles a technical summary from various indicators like MACD, RSI, and StochRSI, along with moving average data. The analysis suggests a "Neutral" signal for …

Tokio Marine Holdings Number of Employees 2026 | Employee Count & Headcount Data

AMN or RTO: Which Is the Better Value Stock Right Now?

Investors interested in Business - Services stocks are likely familiar with AMN Healthcare Services (AMN) and Rentokil Initial PLC (RTO). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. We have found that …

CYTK4910847 Bond Profile — Key Metrics

This article provides a bond profile for CYTK4910847, issued by Cytokinetics, Inc. Key details include its 4.0% coupon rate, November 15, 2026 maturity date, and an outstanding amount of $8.63 million USD. Cytokinetics, Inc. is described as a biopharmaceutical company focused on developing treatments …

Cytokinetics president & CEO Robert Blum sells $606,525 in stock

Cytokinetics President and CEO Robert Blum sold common stock worth $606,525 on July 27, 2026, by disposing of 7,500 shares at $80.87 each. This sale occurred simultaneously with his acquisition of 7,500 shares via a non-qualified stock option exercise at a price of $10.60 …

EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK

EcoR1 Capital LLC acquired 100,000 shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the first quarter, a position valued at $3.26 million. Analysts rate STOK a "Moderate Buy" with an average price target of $43, despite the company reporting losses as it develops genetic medicines. …

Dono de Tok&Stok e Mobly, Grupo Toky (TOKY3) Fará Grupamento de Ações após Papel Cair Abaixo de R$ 1

Why is Tokyo Electron stock tumbling today? By Investing.com

Why is Tokyo Electron stock tumbling today?

Is Cytokinetics (CYTK) Cheap Or Has Its Cardiac Growth Story Already Been Priced In?

Cytokinetics (CYTK) has seen mixed short-term performance but strong 3-month and 1-year returns. Despite a "Most Popular Narrative" suggesting it's 23.7% undervalued with a fair value of $105.60, the company faces risks from ongoing losses, trial outcomes, and high expenses. Investors are encouraged to …

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Stoke Therapeutics announced it will host a webcast and conference call on Monday, August 3, 2026, at 4:30 p.m. ET, to discuss its second quarter 2026 business and financial updates. The company is focused on restoring protein expression using RNA medicine, with its lead …

Stoke Therapeutics Inc (STOK) Cash Flow

This article provides a detailed cash flow statement for Stoke Therapeutics Inc (STOK), covering quarterly and annual data for operating, investing, and financing activities. It presents a comprehensive historical overview of the company's cash flow performance, including net income, operating gains/losses, changes in working …

STOK|Stoke Therapeutics Inc|Price:31.279|Chg%:-0.030

Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Stoke Therapeutics Inc (STOK) focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years and shows no forthcoming dividend data. The page also presents current …

Rentokil Initial PLC (RTO) Cash Flow

This article provides a detailed cash flow statement for Rentokil Initial PLC (RTO), covering annual and quarterly data across operating, investing, and financing activities. It presents key financial metrics such as net income, capital expenditures, and free cash flow over several years. The page …

Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK

Troluce Capital Advisors LLC has acquired 652,800 shares of Stoke

Tokyo Plast International Q1 Results: Standalone profit rises 289% YoY

Cytokinetics Inc (CYTK) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cytokinetics Inc (CYTK) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article also presents …

Rentokil Initial PLC (RTO.L) Stock Analysis: Exploring A 24.79% Potential Upside

Rentokil Initial PLC (RTO.L) offers a potential 24.79% upside, according to analyst sentiment, despite a recent minor price dip. The UK-based company, specializing in pest control, hygiene, and cleaning, currently trades at 426 GBp with an average target price of 531.63 GBp. While revenue …

Does Stoke Therapeutics’ New Genetic Medicine CSO Hire Reframe Its R&D Ambitions for STOK?

Stoke Therapeutics recently appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, bringing over 25 years of R&D and rare disease drug development experience, particularly in genetic and RNA-based medicines. This hire is seen as directionally positive for the company's antisense oligonucleotide programs, including the …

Cytokinetics, Incorporated Revenue Breakdown – BX:KK3A

Cytokinetics, Incorporated (BX:KK3A) reported a total revenue of 69.79 million CHF last year, primarily from its Muscle Activators and Muscle Inhibitors segment. This segment generated the entirety of the reported revenue, a significant increase from 16.78 million CHF in the previous year. The United …

RTO|Rentokil Initial PLC|Price:28.370|Chg%:-0.830

This article provides a detailed financial overview of Rentokil Initial PLC (RTO), including its current stock price, market capitalization, P/E ratios, dividend yield, and performance metrics over various periods. It also highlights analyst ratings, with a strong buy consensus from 4 analysts and a …

CYTK|Cytokinetics Inc|Price:80.740|Chg%:-1.180

Cytokinetics Inc. (CYTK) is a late-stage cardiovascular biopharmaceutical company with strong fundamentals, high growth potential, and a 'Buy' rating from analysts, targeting $107.84. Despite a recent sideways stock performance, the company exhibits high revenue growth, substantial profit growth, and institutional ownership, though it shows …

Rentokil Initial plc Stock 12‑Month Price Target Cut to $35.28, Implies 24% Upside

The average 12-month price target for Rentokil Initial plc stock has been slightly reduced from $35.5 to $35.28, according to estimates from 14 analysts. Despite this cut, the new target still implies approximately 24% potential upside based on the Jul. 24 closing price. The …

Cytokinetics EVP Fady Malik sells $282,065 in company stock By Investing.com

Cytokinetics Executive Vice President of Research & Development, Fady Malik, sold 3,500 shares of company stock for $282,065 and simultaneously acquired 3,500 shares through stock options for $27,300. This follows the European launch of Cytokinetics' heart drug Myqorzo in Germany, with analysts like UBS …

Pest controller Rentokil challenged by slowing US growth - says analyst

Deutsche Bank analysts predict that Rentokil Initial PLC will face challenges in North America due to slowing industry growth in pest control. They expect North American Pest Control organic growth to decline to 3% in Q2 from 4.1% in Q1, influenced by weaker online …

Form 4 Cytokinetics Inc For: 24 July By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for Cytokinetics Inc, dated July 24. It provides a brief announcement of the filing without further details in the main text. The content also includes market data, news headlines, and advertising …

Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK)

Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK), sold 3,500 shares of the company on July 21, 2026. This transaction follows a pattern of insider selling, with 77 insider sells and 0 insider buys over the past year. Cytokinetics …

Cytokinetics Insider Sold Shares Worth $282,065, According to a Recent SEC Filing

An insider at Cytokinetics, Incorporated (CYTK) recently sold shares valued at $282,065, according to a recent SEC filing. This transaction follows several other insider share sales reported in July and June, with values ranging from $266,390 to $1,287,000. Cytokinetics is a biopharmaceutical company focused …

Cytokinetics Will Share Q2 Results Aug. 6, Then Host Live Call

Cytokinetics (Nasdaq: CYTK) announced it will report its second-quarter 2026 financial results on August 6, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. …

Cytokinetics, Incorporated (CYTK) Options Chain

This article provides the options chain data for Cytokinetics, Incorporated (CYTK), including both call and put options with various strike prices and expiration dates for January 21, 2028. It lists detailed information such as last trade date, strike price, last price, bid, ask, change, …

Rentokil Initial slips Thursday, underperforms market

Rentokil Initial PLC (RTO) saw its shares drop by 3.53% to £4.30 on Thursday, underperforming the broader market as the FTSE 100 Index (UKX) also fell. The company's stock is now 15.29% below its 52-week high of £5.07. This decline occurred during an overall …

Stoke Therapeutics appoints Thomas McCauley as Chief Scientific Officer

Stoke Therapeutics has appointed Thomas McCauley as its new Chief Scientific Officer. McCauley brings over 25 years of experience in leading R&D teams and translating scientific discoveries into clinical programs, with extensive expertise in novel technology platforms, particularly in rare diseases and mRNA technologies. …

Rentokil Initial (RTO) Expected to Announce Quarterly Earnings on Thursday